New Targeted Therapy Shows Improved Progression-Free Survival in EGFR-Mutated Lung Cancer

Interim findings from the phase 3 PANKU-Lung01 trial indicate that izalontamab brengitecan (iza-bren) significantly improved progression-free survival (PFS) compared to platinum-based chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC) whose disease progressed on a third-generation EGFR tyrosine kinase inhibitor. The median PFS for iza-bren was 11.1 months versus 5.7 months for chemotherapy. These results were presented at the 2026 ESMO Congress and simultaneously published in The Lancet.